Lantern Pharma is trading 5.18% down at $1.83 after falling from the September 2, 2026 close of $1.93; the cause remains unclear despite broader equities and biotechnology stocks rising.

  • No new company-specific announcement or clear catalyst was identified for September 3, 2026.
  • Recent coverage remains focused on the August 14 second-quarter results and clinical-program updates.